PHILADELPHIA, PA / ACCESSWIRE / November 11, 2024 / The following abrdn U.S. Closed-End Funds (NYSE:ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, JEQ, THQ, THW)(NYSE American:FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on November 29, 2024 to all shareholders of record as of November 21, 2024 (ex-dividend date November 21, 2024). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on January 10, 2025 to all shareholders of record as of November 21, 2024 (ex-dividend date November 21, 2024).

PHILADELPHIA, PA / ACCESSWIRE / September 30, 2024 / The abrdn U.S. Closed-End Funds (NYSE:ASGI, HQH, HQL, IFN, JEQ, THQ) (NYSE American:IAF), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on September 30, 2024, on a per share basis to all shareholders of record as of September 23, 2024 (ex-dividend date September 23, 2024). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund, Inc. (JEQ) which paid on September 30, 2024, to all shareholders of record as of August 23, 2024 (ex-dividend date August 23, 2024), and the abrdn Global Infrastructure Income Fund (ASGI) which paid on September 30, 2024, to all shareholders of record as of September 20, 2024 (ex-dividend date September 20, 2024).

PHILADELPHIA, PA / ACCESSWIRE / August 9, 2024 / The following abrdn U.S. Closed-End Funds (NYSEACP)NYSE:ASGINYSEASGI)(NYSE:AWPNYSEAWP(NYSE:HQHNYSE)(NYSE:HQLHQL)(NYSEIFN)NYSE:JEQNYSEJEQ)(NYSE:THQNYSETHQ(NYSE:THWNYSE)(NYSE American:FAX)(NYSE American:FCO)(NYSE American:IAF)(NYSE American:VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on August 30, 2024 to all shareholders of record as of August 23, 2024 (ex-dividend date August 23, 2024). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on September 30, 2024, to all shareholders of record as of August 23, 2024 (ex-dividend date August 23, 2024).

PHILADELPHIA, PA / ACCESSWIRE / June 26, 2024 / abrdn Life Sciences Investors ("HQL") announced today the results of the Annual Meeting of Shareholders (the "Meeting"), held on June 25, 2024.

PHILADELPHIA, PA / ACCESSWIRE / June 28, 2024 / PHILADELPHIA, PA / ACCESSWIRE / June 28, 2024 / The abrdn U.S. Closed-End Funds (NYSEASGI)NYSE:HQHNYSEHQH)(NYSE:HQLNYSEHQL(NYSE:JEQNYSE)(NYSE:THQTHQ)(NYSETHW)(NYSE American:IAF), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on June 28, 2024, on a per share basis to all shareholders of record as of June 21, 2024 (ex-dividend date June 21, 2024). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and abrdn Japan Equity Fund, Inc. (JEQ) which will pay on June 28, 2024, to all shareholders of record as of May 23, 2024 (ex-dividend date May 22, 2024).

PHILADELPHIA, PA / ACCESSWIRE / March 28, 2024 / The abrdn U.S. Closed-End Funds (NYSE:ASGI, HQH, HQL, IFN, JEQ, THQ, THW) (NYSE American:IAF), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on March 28, 2024, on a per share basis to all shareholders of record as of March 21, 2024 (ex-dividend date March 20, 2024). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on March 28, 2024, to all shareholders of record as of February 22, 2024 (ex-dividend date February 21, 2024).

PHILADELPHIA, PA / ACCESSWIRE / March 21, 2024 / abrdn Healthcare Investors (NYSEHQH), abrdn Life Sciences Investors NYSE:HQLNYSEHQL)(NYSE:THQNYSETHQ, and abrdn World Healthcare Fund (NYSE:THWNYSE) (collectively, the "Funds") each, a closed-end management investment company, announced today the appointment of Dr. Jason Akus as co-lead portfolio manager to the Funds alongside Dr. Daniel Omstead. Dr. Akus has served on the investment team with Dr. Omstead for over 20 years.

PHILADELPHIA, PA / ACCESSWIRE / February 9, 2024 / abrdn Life Sciences Investors (HQL), abrdn Healthcare Investors (HQH), and abrdn Healthcare Opportunities Fund (THQ) (collectively, the "Funds") each, a closed-end management investment company, announced today its Board of Trustees (each a "Board" and collectively, the "Boards") have approved an increase in each Fund's respective distribution rate and announce payment details for the Funds in the chart directly below.

PHILADELPHIA, PA / ACCESSWIRE / January 10, 2024 / PHILADELPHIA, PA / ACCESSWIRE / January 10, 2024 / The abrdn U.S. Closed-End Funds (NYSE:ASGI, IFN, JEQ) (NYSE American:HQH, HQL, IAF, THQ, THW), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on January 10, 2024, on a per share basis to all shareholders of record as of December 29, 2023 (ex-dividend date December 28, 2023). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF), the India Fund, Inc. (IFN) and the abrdn Japan Equity Fund, Inc. (JEQ) which will pay on January 10, 2024, to all shareholders of record as of November 22, 2023 (ex-dividend date November 21, 2023).

HQH, HQL, THQ, THW

Tekla Capital Management LLC (Tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its four closed-end funds (the Funds).

PHILADELPHIA, PA / ACCESSWIRE / October 27, 2023 / Effective close of business today, October 27, 2023, abrdn Inc. ("abrdn") assumed responsibility for the management of the four (4) former Tekla Capital Management LLC closed-end funds totaling $2.8bn in assets under management (AUM) as of October 26, 2023. As noted within the Funds' proxy statements and in connection with the change in investment adviser, each Fund amended its declaration of trust to change its name as detailed in the chart below effective after close of regular business on October 27, 2023. Each Fund's shares are listed on the New York Stock Exchange and the ticker symbols and CUSIPs will not change as a result of this transaction.

Tekla Healthcare Investors (HQH) today announced at the Special Meetings of shareholders (“Special Meetings”) that the requisite vote had been attained for the proposal to approve the new investment advisory agreement with abrdn Inc.

Tekla Life Sciences Investors (HQL) announced at the Joint Special Meetings of shareholders (“Special Meetings”) that the requisite vote had been reached to approve the new investment advisory agreement with abrdn Inc.

On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $44,305,054, of which $10,004,278 represents net unrealized appreciation of portfolio securities.

Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint first special meetings of shareholders (“Special Meetings”) were adjourned again until October 3, 2023 at 9:00 a.m. EDT.

Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint first special meetings of shareholders (“Special Meetings”) were adjourned for a second time until September 12, 2023 at 9:00 a.m. EDT due to lack of a quorum on the proposal to approve a new investment advisory agreement with abrdn, Inc. Shareholders as of the June 16, 2023 record date who have not yet voted on the Proposal are urged to do so promptly per the instructions below.

On August 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.32 per share. The record date for the distribution is August 25, 2023 and the payable date is September 29, 2023. The Fund will trade ex-distribution on August 24, 2023.

Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today announced that their joint special meetings of shareholders on August 14, 2023 (“Special Meetings”) were adjourned until August 29, 2023 to provide additional time for the Funds to reach a quorum on the proposal, described in their definitive joint proxy statement dated July 10, 2023 as filed with the Securities and Exchange Commission (the “Proxy Statement”), to approve a new investment advisory agreement with abrdn, Inc. (the “Proposal”). The adjourned Special Meeting will recommence on August 29, 2023 at 9:00 a.m. EDT at the offices of the Funds, 100 Federal Street, Boston, MA. The record date for the adjourned Special Meetings remains the same, June 16, 2023.

On June 30, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $67,628,377, of which $60,437,904 represents net unrealized appreciation of portfolio securities.

PHILADELPHIA, PA / ACCESSWIRE / June 20, 2023 / abrdn plc today announced that its U.S. subsidiary abrdn Inc. has entered into an agreement to acquire the healthcare fund management capabilities of Tekla Capital Management LLC (Tekla), a global specialist healthcare investment adviser based in Boston, Massachusetts. The deal includes four NYSE listed healthcare and biotech thematic closed-end funds, totalling c.$3bn[1]in assets under management (AUM), with c.$30m revenues in 2022.

Tekla Capital Management LLC (Tekla) announced today that it has entered into an agreement with abrdn Inc. for a strategic transaction involving four NYSE-listed healthcare & biotech thematic closed-end funds (the Funds), totaling $3.1 bn in assets under management.1

On May 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.32 per share. The record date for the distribution is May 25, 2023 and the payable date is June 30, 2023. The Fund will trade ex-distribution on May 24, 2023.